140 related articles for article (PubMed ID: 7493924)
1. Evidence that aspartic acid 301 is a critical substrate-contact residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Smith G; Lightfoot T; Wong MM; Simula AP; Ackland MJ; Sternberg MJ; Lennard MS; Tucker GT
J Biol Chem; 1995 Dec; 270(49):29055-8. PubMed ID: 7493924
[TBL] [Abstract][Full Text] [Related]
2. Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6.
Ellis SW; Hayhurst GP; Lightfoot T; Smith G; Harlow J; Rowland-Yeo K; Larsson C; Mahling J; Lim CK; Wolf CR; Blackburn MG; Lennard MS; Tucker GT
Biochem J; 2000 Feb; 345 Pt 3(Pt 3):565-71. PubMed ID: 10642515
[TBL] [Abstract][Full Text] [Related]
3. Active-site topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants.
Mackman R; Tschirret-Guth RA; Smith G; Hayhurst GP; Ellis SW; Lennard MS; Tucker GT; Wolf CR; Ortiz de Montellano PR
Arch Biochem Biophys; 1996 Jul; 331(1):134-40. PubMed ID: 8660692
[TBL] [Abstract][Full Text] [Related]
4. A predictive model for substrates of cytochrome P450-debrisoquine (2D6).
Koymans L; Vermeulen NP; van Acker SA; te Koppele JM; Heykants JJ; Lavrijsen K; Meuldermans W; Donné-Op den Kelder GM
Chem Res Toxicol; 1992; 5(2):211-9. PubMed ID: 1379482
[TBL] [Abstract][Full Text] [Related]
5. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding.
Guengerich FP; Miller GP; Hanna IH; Martin MV; Léger S; Black C; Chauret N; Silva JM; Trimble LA; Yergey JA; Nicoll-Griffith DA
Biochemistry; 2002 Sep; 41(36):11025-34. PubMed ID: 12206675
[TBL] [Abstract][Full Text] [Related]
6. Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6.
Hayhurst GP; Harlow J; Chowdry J; Gross E; Hilton E; Lennard MS; Tucker GT; Ellis SW
Biochem J; 2001 Apr; 355(Pt 2):373-9. PubMed ID: 11284724
[TBL] [Abstract][Full Text] [Related]
7. A model for human cytochrome P450 2D6 based on homology modeling and NMR studies of substrate binding.
Modi S; Paine MJ; Sutcliffe MJ; Lian LY; Primrose WU; Wolf CR; Roberts GC
Biochemistry; 1996 Apr; 35(14):4540-50. PubMed ID: 8605204
[TBL] [Abstract][Full Text] [Related]
8. Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol.
Ellis SW; Rowland K; Ackland MJ; Rekka E; Simula AP; Lennard MS; Wolf CR; Tucker GT
Biochem J; 1996 Jun; 316 ( Pt 2)(Pt 2):647-54. PubMed ID: 8687412
[TBL] [Abstract][Full Text] [Related]
9. Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.
Paine MJ; McLaughlin LA; Flanagan JU; Kemp CA; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2003 Feb; 278(6):4021-7. PubMed ID: 12446689
[TBL] [Abstract][Full Text] [Related]
10. Why is quinidine an inhibitor of cytochrome P450 2D6? The role of key active-site residues in quinidine binding.
McLaughlin LA; Paine MJ; Kemp CA; Maréchal JD; Flanagan JU; Ward CJ; Sutcliffe MJ; Roberts GC; Wolf CR
J Biol Chem; 2005 Nov; 280(46):38617-24. PubMed ID: 16162505
[TBL] [Abstract][Full Text] [Related]
11. Critical residues involved in FMN binding and catalytic activity in cytochrome P450BM-3.
Klein ML; Fulco AJ
J Biol Chem; 1993 Apr; 268(10):7553-61. PubMed ID: 8463285
[TBL] [Abstract][Full Text] [Related]
12. A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building.
Koymans LM; Vermeulen NP; Baarslag A; Donné-Op den Kelder GM
J Comput Aided Mol Des; 1993 Jun; 7(3):281-9. PubMed ID: 8377025
[TBL] [Abstract][Full Text] [Related]
13. A refined substrate model for human cytochrome P450 2D6.
de Groot MJ; Bijloo GJ; Martens BJ; van Acker FA; Vermeulen NP
Chem Res Toxicol; 1997 Jan; 10(1):41-8. PubMed ID: 9074801
[TBL] [Abstract][Full Text] [Related]
14. A three-dimensional molecular template for substrates of human cytochrome P450 involved in debrisoquine 4-hydroxylation.
Islam SA; Wolf CR; Lennard MS; Sternberg MJ
Carcinogenesis; 1991 Dec; 12(12):2211-9. PubMed ID: 1747920
[TBL] [Abstract][Full Text] [Related]
15. A three-dimensional protein model for human cytochrome P450 2D6 based on the crystal structures of P450 101, P450 102, and P450 108.
de Groot MJ; Vermeulen NP; Kramer JD; van Acker FA; Donné-Op den Kelder GM
Chem Res Toxicol; 1996; 9(7):1079-91. PubMed ID: 8902262
[TBL] [Abstract][Full Text] [Related]
16. Diversity in mechanisms of substrate oxidation by cytochrome P450 2D6. Lack of an allosteric role of NADPH-cytochrome P450 reductase in catalytic regioselectivity.
Hanna IH; Krauser JA; Cai H; Kim MS; Guengerich FP
J Biol Chem; 2001 Oct; 276(43):39553-61. PubMed ID: 11509577
[TBL] [Abstract][Full Text] [Related]
17. Heterologous expression of cytochrome P450 2D6 mutants, electron transfer, and catalysis of bufuralol hydroxylation: the role of aspartate 301 in structural integrity.
Hanna IH; Kim MS; Guengerich FP
Arch Biochem Biophys; 2001 Sep; 393(2):255-61. PubMed ID: 11556812
[TBL] [Abstract][Full Text] [Related]
18. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
19. Role of glutamic acid 216 in cytochrome P450 2D6 substrate binding and catalysis.
Guengerich FP; Hanna IH; Martin MV; Gillam EM
Biochemistry; 2003 Feb; 42(5):1245-53. PubMed ID: 12564927
[TBL] [Abstract][Full Text] [Related]
20. Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.
Flanagan JU; Maréchal JD; Ward R; Kemp CA; McLaughlin LA; Sutcliffe MJ; Roberts GC; Paine MJ; Wolf CR
Biochem J; 2004 Jun; 380(Pt 2):353-60. PubMed ID: 14992686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
